Amicus Therapeutics, a biotechnology enterprise, is committed to the research, development, and commercialization of therapeutic solutions for rare genetic conditions. Its flagship commercial product, Galafold, is a precise, orally administered medication intended for adult patients with a verified diagnosis of Fabry disease who possess a treatable galactosidase alpha gene variant, as indicated by in vitro laboratory assays. The company's robust development pipeline features AT-GAA, an innovative therapeutic approach for Pompe disease, in addition to other enzyme replacement therapies targeting this same condition.